safety and efficacy of pegylated interferon alfa-2a for the treatment of hepatitis c in patients with major thalassemia
نویسندگان
چکیده
background: hepatitis c virus (hcv) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. in this study we aimed to evaluate the effects of pegylated interferon alfa-2a (peg-ifn a-2a) in reducing serum alt and eradicating serum hepatitis c virus (hcv) rna in hcv infected polytransfused thalassemic patients. materials and methods: a cohort of 51 hcv-rna positive thalassemic patients were enrolled to our study and received 180 µg peg-ifn a-2a once-weekly for 48 weeks. the primary end point was sustained virological response (svr). the secondary outcome was normalization of alt. patient safety was assured by monthly, and if needed, weekly laboratory assessment and visits. results: of 52 patients, 42 participants completed the treatment schedule. a sustained virological response (svr) was attained in 22/51 (43%) cases. among non-responders or relapsers to previous hcv antiviral therapy, 9/27 (33%) attained an svr. five patients died during treatment and 3 subjects discontinued the therapy because of adverse effects. adverse events were generally mild, and laboratory abnormalities were rare. conclusion: a course of 48-week peg-ifn a-2a monotherapy is effective in eradicating hcv-rna during treatment. but about one third of thalassemic patients would relapse within 6 months of treatment schedule completion, in whom combination therapy is needed.
منابع مشابه
Safety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia
Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients. Materials and Methods: A cohort of 51 HCV-...
متن کاملSafety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.
Antiviral treatment of hepatitis C virus in thalassemia has raised concerns of ribavirin-induced hemolysis and increased iron loading. This study examined the change in liver iron concentration, transfusion requirement, virological response, and iron-related toxicities after pegylated interferon alpha-2a/ribavirin treatment in patients with thalassemia. Median transfusions increased by 44%. How...
متن کاملSAFETY AND EFFICACY OF INTERFERON ALFA FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED SUBJECTS WITH TRANSFUSION DEPENDENT THALASSEMIA IN IRAN
Up to 30% of Iranian adult multi-transfused thalassemic patients are infected with hepatitis C virus (HCV) which can intensify the progression of liver disease caused by iron overload in this group of patients. Our aim was to assess the biochemical and virological response of interferon alfa (INF-α) and its safety in thalassemic patients with chronic HCV infection. This trial was a single c...
متن کاملEfficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
AIM To evaluate the efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. METHODS Thirty-six hemodialysis patients with chronic hepatitis C were enrolled in a controlled and prospective study. All patients were treatment naive, positive tested for anti-HCV antibodies, and positive tested for serum HCV-RNA. Twenty-two patients received 135 micr...
متن کاملA MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HEBER ON (INTERFERON ALFA-2b) IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN IRAN
ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...
متن کاملAntiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
OBJECTIVES To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. PATIENTS AND METHODS In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 ...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian journal of blood and cancerجلد ۱، شماره ۴، صفحات ۱۲۹-۱۳۷
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023